Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Bristol Myers Faces $6.7 Billion Lawsuit After Judge Allows Key Shareholder Claims to Proceed 
Federal Judge Blocks Trump Administration’s Medicaid Funding Restrictions Targeting Planned Parenthood 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Afghan Suspect in Deadly Shooting of National Guard Members Faces First-Degree Murder Charge 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Bolsonaro Detained Over Alleged Escape Risk After Ankle Monitor Tampering 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Intel Rejects TSMC’s Allegations of Trade-Secret Leaks as Legal Battle Escalates 
Union Urges Court to Compel Trump Administration to Restore CFPB Funding 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Rite Aid has sued the U.S. Department of Justice (DOJ) to halt a lawsuit alleging the company's involvement in illegally filling prescriptions for addictive opioid medications. The lawsuit comes as Rite Aid finds itself in a bankruptcy situation.
Reuters reported that the DOJ's position threatens to impede the ongoing restructuring efforts by the company. In response, Rite Aid has requested the U.S. Bankruptcy Judge Michael Kaplan will rule that the DOJ lawsuit should not proceed while the company is under bankruptcy protection.
DOJ's Lawsuit Pause and Rite Aid's Request for Equal Treatment
The DOJ had initially filed the lawsuit against Rite Aid in March, and despite Rite Aid's bankruptcy filing, it agreed to a "brief pause" of the lawsuit, according to PennLive. However, Rite Aid argues that this stance undermines its restructuring efforts.
Rite Aid seeks to put the government on equal footing with other opioid-related plaintiffs whose lawsuits were automatically halted due to the company's bankruptcy filing. The DOJ maintains that its lawsuit is not affected by the bankruptcy filing as it exercises its "police powers" through legal action.
Rite Aid, which operates approximately 2,000 retail pharmacies across 17 U.S. states, filed for bankruptcy protection in October. It aims to close underperforming stores and address over 1,600 lawsuits surrounding allegations of over-selling addictive opioid medications by filling illegal or suspicious prescriptions. However, a court-appointed committee representing opioid plaintiffs has expressed concerns over potential non-payment to victims harmed by Rite Aid's alleged reckless sale of opioid drugs.
Rite Aid's Legal Battle Implications
As Rite Aid fights the DOJ's lawsuit, the outcome will have far-reaching implications. It will determine whether the company can proceed with its restructuring efforts unhampered by legal actions, and if the DOJ's exercise of "police powers" can continue despite Rite Aid's bankruptcy status.
Additionally, the opioid creditors and victims affected by the company's alleged actions will closely monitor the proceedings, hoping for equitable resolutions.
Attorney Arik Preiss, representing opioid creditors, raised concerns that Rite Aid's bankruptcy proceedings seem to prioritize its top lenders over other stakeholders, potentially putting them at odds with the DOJ.
Rite Aid's major competitors, including Walgreens, Walmart, and CVS, have already agreed to settle a series of similar opioid lawsuits outside of bankruptcy, amounting to $13.8 billion.
The DOJ's opposition to opioid settlements in the bankruptcies of Endo International and Purdue Pharma has complicated those cases as well, delaying proposed settlements and drawing appeals to higher courts.
Photo: Rite Aid Newsroom
